Originally published by NBC News View Original Article
White House drops Heidi Overton’s FDA nomination after Republicans raise concerns

White House drops Heidi Overton’s FDA nomination after Republicans raise concerns

WASHINGTON — The White House is dropping Dr. Heidi Overton’s nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday.

The decision comes a day before the Senate Health Committee was scheduled to vote on whether to advance her nomination to the full Senate for confirmation.

Axios first reported the White House’s decision.

The move follows weeks of doubts from key Republicans on the Health, Education, Pensions and Labor Committee. To advance to the full Senate, Overton would have needed 11 votes in the 21-member committee, meaning she couldn’t afford to lose a single Republican if all Democrats opposed her.

Sen. Bill Cassidy of Louisiana, the committee’s chairman, questioned whether Overton — a preventive medicine doctor who serves as a domestic policy official in the White House — had enough experience to lead the agency.

Before Overton’s confirmation hearing in September, Cassidy wrote on X that he had “strong concerns” about her nomination, saying her lack of managerial experience left her poorly prepared to lead the agency. In a post last week, Cassidy said he remained undecided.

Prior to joining the White House, Overton worked as chief policy officer at the conservative think tank America First Policy Institute.

Sen. Susan Collins, R-Maine, told NBC News last week that she was undecided and had “not taken a position,” saying she needed “to get some answers on various things.”

Sen. Lisa Murkowski of Alaska declined last week to say how she’d vote. During the confirmation hearing, Murkowski asked Overton about political pressure surrounding access to mifepristone, and criticized Overton for not taking a clear position on the subject.

Overton has praised the Supreme Court’s decision to overturn Roe v. Wade and called for strict restrictions on medication abortion.

The FDA is set to finish its safety review of mifepristone in March, one of the most consequential decisions the agency faces.

Overton’s nomination was already working against a tight window. Democrats take control of the Senate in January, when she would have to be renominated, and her chances of being confirmed then would be slim.

The FDA has been without a permanent commissioner since Dr. Marty Makary resigned in May, in part because of the administration’s decision to authorize several fruit-flavored vaping products.

The vacancy adds to a long period of upheaval at the nation’s top health agencies.

The Centers for Disease Control and Prevention went nearly a year without a permanent director after Health Secretary Robert F. Kennedy Jr. removed Susan Monarez just 29 days into the job last year. Trump’s first pick for that role, former congressman Dave Weldon, couldn’t secure enough Republican support, and the agency cycled through a series of acting leaders before the Senate confirmed Dr. Erica Schwartz in August.

Read the original article at NBC News →